esmo
presentation
shows
cemiplimab
monotherapy
increases
overall
survival
advanced
cell
lung
cancer
expression
esmo
presentation
shows
cemiplimab
monotherapy
increases
overall
survival
advanced
cell
lung
cancer
expression
overall
trial
population
libtayo
reduced
risk
death
compared
chemotherapy
prespecified
analysis
patients
confirmed
expression
libtayo
reduced
risk
death
paris
tarrytown
september
positive
pivotal
trial
data
investigational
use
inhibitor
cemiplimab
locally
advanced
metastatic
cell
lung
cancer
nsclc
shared
presentation
european
society
medical
oncology
esmo
virtual
congress
trial
compared
libtayo
monotherapy
chemotherapy
patients
whose
tumor
cells
expressed
including
whose
cancers
confirmed
expression
results
form
basis
regulatory
submissions
including
european
union
new
analyses
presented
esmo
libtayo
reduced
risk
death
patients
whose
cancer
confirmed
expression
greater
notable
given
nearly
patients
crossed
chemotherapy
following
disease
progression
patients
pretreated
stable
brain
metastases
said
ahmet
sezer
associate
professor
department
medical
oncology
ba≈ükent
university
adana
turkey
trial
investigator
results
support
libtayo
potential
new
option
monotherapy
advanced
cell
lung
esmo
presentation
expands
topline
results
shared
april
overall
trial
population
median
months
libtayo
range
months
chemotherapy
range
months
among
patients
libtayo
demonstrated
following
results
compared
chemotherapy
reduced
risk
death
hazard
ratio
hr
confidence
interval
ci
hazard
ratio
hr
confidence
interval
ci
median
overall
survival
os
ci
months
yet
evaluable
compared
months
ci
months
os
ci
months
yet
evaluable
compared
months
ci
months
reduced
risk
disease
progression
ci
p
median
survival
pfs
months
ci
months
compared
months
ci
months
ci
p
median
survival
pfs
months
ci
months
compared
months
ci
months
objective
response
rate
orr
ci
complete
response
cr
partial
response
pr
rate
compared
orr
ci
cr
pr
rate
prespecified
analysis
data
patients
whose
cancers
confirmed
expression
also
conducted
group
median
months
libtayo
range
months
chemotherapy
range
months
libtayo
demonstrated
following
results
compared
chemotherapy
reduced
risk
death
ci
ci
median
os
yet
reached
ci
months
yet
evaluable
compared
months
ci
months
ci
months
yet
evaluable
compared
months
ci
months
reduced
risk
disease
progression
ci
p
median
pfs
months
ci
months
compared
months
ci
months
ci
p
median
pfs
months
ci
months
compared
months
ci
months
orr
ci
cr
pr
rate
compared
orr
ci
cr
pr
rate
trial
also
found
direct
correlation
tumor
response
expression
level
patients
orr
highest
range
tumors
expression
target
tumors
shrinking
months
treatment
average
per
last
observation
carried
forward
method
correlation
expression
level
observed
chemotherapy
overall
trial
population
median
duration
exposure
libtayo
weeks
range
weeks
weeks
chemotherapy
range
weeks
overall
adverse
events
aes
occurred
libtayo
patients
chemotherapy
patients
grade
higher
aes
occurred
libtayo
patients
chemotherapy
patients
aes
reported
libtayo
patients
included
hypothyroidism
hyperthyroidism
pneumonitis
hepatitis
skin
adverse
reaction
arthritis
increased
blood
thyroid
stimulating
hormone
thyroiditis
colitis
nephritis
peripheral
neuropathy
treatment
discontinuation
due
ae
occurred
libtayo
patients
chemotherapy
patients
new
libtayo
safety
signals
observed
libtayo
jointly
developed
regeneron
sanofi
global
collaboration
agreement
use
libtayo
treat
advanced
nsclc
investigational
fully
evaluated
regulatory
authority
phase
trial
randomized
phase
trial
investigated
treatment
libtayo
monotherapy
compared
chemotherapy
squamous
advanced
nsclc
tested
positive
tumor
cells
alk
egfr
expression
confirmed
using
ihc
pharmdx
kit
trial
included
patients
either
locally
advanced
nsclc
stage
iiib
c
candidates
surgical
resection
definitive
chemoradiation
progressed
treatment
definitive
chemoradiation
previously
untreated
metastatic
nsclc
stage
iv
patients
randomized
receive
either
libtayo
mg
administered
intravenously
every
three
weeks
weeks
doublet
chemotherapy
regimen
cycles
without
histology
relevant
maintenance
pemetrexed
chemotherapy
endpoints
os
pfs
secondary
endpoints
include
overall
response
rate
duration
response
quality
life
trial
designed
reflect
current
emerging
treatment
paradigms
inclusion
criteria
allowed
patients
nsclc
controlled
hepatitis
b
hepatitis
c
hiv
stable
brain
metastases
locally
advanced
disease
progressed
definitive
chemoradiation
patients
whose
disease
progressed
trial
able
change
therapy
chemotherapy
arm
allowed
crossover
libtayo
arm
libtayo
arm
allowed
combine
libtayo
treatment
cycles
chemotherapy
prespecified
interim
analysis
performed
os
events
due
highly
significant
improvement
os
interim
analysis
trial
modified
allow
patients
receive
libtayo
based
independent
data
monitoring
committee
recommendation
cell
lung
cancer
lung
cancer
leading
cause
cancer
death
worldwide
million
new
cases
expected
globally
approximately
lung
cancers
nsclc
estimated
cases
expected
test
positive
tumor
cells
immunotherapies
transformed
advanced
nsclc
treatment
recent
years
remains
unmet
need
optimize
identification
treatment
patients
high
expression
offer
additional
treatment
options
libtayo
libtayo
monoclonal
antibody
targeting
immune
checkpoint
receptor
binding
libtayo
shown
block
cancer
cells
using
pathway
suppress
activation
libtayo
first
immunotherapy
approved
eu
countries
adults
metastatic
cutaneous
squamous
cell
carcinoma
cscc
locally
advanced
cscc
candidates
curative
surgery
curative
radiation
generic
name
libtayo
approved
indication
rwlc
suffix
designated
accordance
nonproprietary
naming
biological
products
guidance
industry
issued
food
drug
administration
outside
generic
name
libtayo
approved
indication
cemiplimab
extensive
clinical
program
libtayo
focused
cancers
skin
cancer
includes
trials
adjuvant
neoadjuvant
cscc
addition
pivotal
trial
advanced
bcc
libtayo
also
investigated
pivotal
trials
nsclc
cervical
cancer
well
trials
combining
libtayo
either
conventional
novel
therapeutic
approaches
solid
tumors
blood
cancers
potential
uses
investigational
safety
efficacy
evaluated
regulatory
authority
regeneron
pharmaceuticals
regeneron
nasdaq
regn
leading
biotechnology
company
invents
medicines
people
serious
diseases
founded
led
years
unique
ability
repeatedly
consistently
translate
science
medicine
led
seven
treatments
numerous
product
candidates
development
homegrown
laboratories
medicines
pipeline
designed
help
patients
eye
diseases
allergic
inflammatory
diseases
cancer
cardiovascular
metabolic
diseases
pain
infectious
diseases
rare
diseases
regeneron
accelerating
improving
traditional
drug
development
process
proprietary
technologies
velocimmune
uses
unique
mice
produce
optimized
antibodies
bispecific
antibodies
ambitious
research
initiatives
regeneron
genetics
center
conducting
one
largest
genetics
sequencing
efforts
world
additional
information
company
please
visit
follow
regeneron
twitter
sanofi
sanofi
dedicated
supporting
people
health
challenges
global
biopharmaceutical
company
focused
human
health
prevent
illness
vaccines
provide
innovative
treatments
fight
pain
ease
suffering
stand
suffer
rare
diseases
millions
chronic
conditions
people
countries
sanofi
transforming
scientific
innovation
healthcare
solutions
around
globe
sanofi
empowering
life
sanofi
media
relations
contact
sally
bain
tel
regeneron
media
relations
contact
daren
kwok
tel
sanofi
investor
relations
contacts
paris
eva
arnaud
delepine
yvonne
naughton
sanofi
investor
relations
contacts
north
america
felix
lauscher
fara
berkowitz
suzanne
greco
ir
main
line
tel
ir
regeneron
investor
relations
contact
vesna
tosic
tel
sanofi
statements
press
release
contains
statements
defined
private
securities
litigation
reform
act
amended
statements
statements
historical
facts
statements
include
projections
estimates
regarding
marketing
potential
product
regarding
potential
future
revenues
product
statements
generally
identified
words
expects
anticipates
believes
intends
estimates
plans
similar
expressions
although
sanofi
management
believes
expectations
reflected
statements
reasonable
investors
cautioned
information
statements
subject
various
risks
uncertainties
many
difficult
predict
generally
beyond
control
sanofi
could
cause
actual
results
developments
differ
materially
expressed
implied
projected
information
statements
risks
uncertainties
include
among
things
unexpected
regulatory
actions
delays
government
regulation
generally
could
affect
availability
commercial
potential
product
fact
product
may
commercially
successful
uncertainties
inherent
research
development
including
future
clinical
data
analysis
existing
clinical
data
relating
product
including
post
marketing
unexpected
safety
quality
manufacturing
issues
competition
general
risks
associated
intellectual
property
related
future
litigation
ultimate
outcome
litigation
volatile
economic
market
conditions
impact
us
customers
suppliers
vendors
business
partners
financial
condition
one
well
employees
global
economy
whole
material
effect
foregoing
could
also
adversely
impact
us
situation
changing
rapidly
additional
impacts
may
arise
currently
aware
may
exacerbate
previously
identified
risks
risks
uncertainties
also
include
uncertainties
discussed
identified
public
filings
sec
amf
made
sanofi
including
listed
risk
factors
cautionary
statement
regarding
statements
sanofi
annual
report
form
year
ended
december
required
applicable
law
sanofi
undertake
obligation
update
revise
information
statements
regeneron
statements
use
digital
media
press
release
includes
statements
involve
risks
uncertainties
relating
future
events
future
performance
regeneron
pharmaceuticals
regeneron
company
actual
events
results
may
differ
materially
statements
words
anticipate
expect
intend
plan
believe
seek
estimate
variations
words
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
concern
risks
uncertainties
include
among
others
impact
virus
caused
pandemic
regeneron
business
employees
collaborators
suppliers
third
parties
regeneron
relies
regeneron
collaborators
ability
continue
conduct
research
clinical
programs
regeneron
ability
manage
supply
chain
net
product
sales
products
marketed
regeneron
collaborators
collectively
regeneron
products
global
economy
nature
timing
possible
success
therapeutic
applications
regeneron
products
regeneron
product
candidates
research
clinical
programs
underway
planned
including
without
limitation
cemiplimab
likelihood
timing
scope
possible
regulatory
approval
commercial
launch
regeneron
product
candidates
new
indications
regeneron
products
libtayo
treatment
cell
lung
cancer
basal
cell
carcinoma
adjuvant
neoadjuvant
cutaneous
squamous
cell
carcinoma
cervical
cancer
well
trials
combining
libtayo
either
conventional
novel
therapeutic
approaches
solid
tumors
blood
cancers
applicable
uncertainty
market
acceptance
commercial
success
regeneron
products
product
candidates
impact
studies
whether
conducted
regeneron
others
whether
mandated
voluntary
commercial
success
regeneron
products
product
candidates
safety
issues
resulting
administration
regeneron
products
libtayo
product
candidates
patients
including
serious
complications
side
effects
connection
use
regeneron
products
product
candidates
clinical
trials
determinations
regulatory
administrative
governmental
authorities
may
delay
restrict
regeneron
ability
continue
develop
commercialize
regeneron
products
product
candidates
ongoing
regulatory
obligations
oversight
impacting
regeneron
products
research
clinical
programs
business
including
relating
patient
privacy
availability
extent
reimbursement
regeneron
products
payers
including
private
payer
healthcare
insurance
programs
health
maintenance
organizations
pharmacy
benefit
management
companies
government
programs
medicare
medicaid
coverage
reimbursement
determinations
payers
new
policies
procedures
adopted
payers
competing
drugs
product
candidates
may
superior
cost
effective
regeneron
products
product
candidates
extent
results
research
development
programs
conducted
regeneron
collaborators
may
replicated
studies
lead
advancement
product
candidates
clinical
trials
therapeutic
applications
regulatory
approval
ability
regeneron
manufacture
manage
supply
chains
multiple
products
product
candidates
ability
regeneron
collaborators
suppliers
third
parties
applicable
perform
manufacturing
filling
finishing
packaging
labeling
distribution
steps
related
regeneron
products
product
candidates
unanticipated
expenses
costs
developing
producing
selling
products
ability
regeneron
meet
financial
projections
guidance
changes
assumptions
underlying
projections
guidance
potential
license
collaboration
agreement
including
regeneron
agreements
sanofi
bayer
teva
pharmaceutical
industries
respective
affiliated
companies
applicable
cancelled
terminated
without
product
success
risks
associated
intellectual
property
parties
pending
future
litigation
relating
thereto
including
without
limitation
patent
litigation
related
proceedings
relating
aflibercept
injection
dupilumab
alirocumab
litigation
proceedings
government
investigations
relating
company
operations
ultimate
outcome
proceedings
investigations
impact
foregoing
may
regeneron
business
prospects
operating
results
financial
condition
complete
description
material
risks
found
regeneron
filings
securities
exchange
commission
including
form
year
ended
december
form
quarterly
period
ended
june
statements
made
based
management
current
beliefs
judgment
reader
cautioned
rely
statements
made
regeneron
regeneron
undertake
obligation
update
publicly
statement
including
without
limitation
financial
projection
guidance
whether
result
new
information
future
events
otherwise
regeneron
uses
media
investor
relations
website
social
media
outlets
publish
important
information
company
including
information
may
deemed
material
investors
financial
information
regeneron
routinely
posted
accessible
regeneron
media
investor
relations
website
http
twitter
feed
http
regeneron
attachment
